<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bisphosphonates for the treatment of osteoporosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bisphosphonates for the treatment of osteoporosis</h1>
<div class="graphic"><div class="figure"><div class="ttl">Bisphosphonates for the treatment of osteoporosis</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1">Bisphosphonate</td> <td class="subtitle1">Formulations</td> <td class="subtitle1">Dosing</td> <td class="subtitle1">Vertebral fracture<br/> reduction</td> <td class="subtitle1">Hip fracture<br/> reduction</td> <td class="subtitle1">Nonvertebral fracture<br/> reduction</td> <td class="subtitle1">Discontinuation of therapy<br/> (in selected patients*); after:</td> </tr> <tr class="divider_bottom"> <td style="vertical-align: middle;">Alendronate</td> <td style="vertical-align: middle;">Oral<sup>¶</sup></td> <td> <ul> <li>10 mg once daily, <strong>or</strong></li> <li>70 mg once weekly<sup>Δ</sup></li> </ul> </td> <td class="centered" style="vertical-align: middle;">Yes</td> <td class="centered" style="vertical-align: middle;">Yes</td> <td class="centered" style="vertical-align: middle;">Yes</td> <td style="vertical-align: middle;">5 years</td> </tr> <tr class="divider_bottom"> <td rowspan="2" style="vertical-align: middle;">Risedronate</td> <td style="vertical-align: middle;">Oral, immediate release<sup>¶</sup></td> <td> <ul> <li>5 mg once daily, <strong>or</strong></li> <li><span style="white-space: nowrap;">35 mg once weekly, <strong>or</strong></span></li> <li>150 mg once monthly</li> </ul> </td> <td class="centered" rowspan="2" style="vertical-align: middle;">Yes</td> <td class="centered" rowspan="2" style="vertical-align: middle;">Yes</td> <td class="centered" rowspan="2" style="vertical-align: middle;">Yes</td> <td style="vertical-align: middle;">5 years<sup>◊</sup></td> </tr> <tr class="divider_bottom"> <td style="vertical-align: middle;">Oral, delayed-release (enteric-coated)<sup>§</sup></td> <td> <ul> <li>35 mg once weekly</li> </ul> </td> <td style="vertical-align: middle;">5 years<sup>◊</sup></td> </tr> <tr class="divider_bottom"> <td style="vertical-align: middle;">Zoledronic acid</td> <td style="vertical-align: middle;">Intravenous</td> <td> <ul> <li>5 mg once every 12 months</li> </ul> </td> <td class="centered" style="vertical-align: middle;">Yes</td> <td class="centered" style="vertical-align: middle;">Yes</td> <td class="centered" style="vertical-align: middle;">Yes</td> <td style="vertical-align: middle;">3 years</td> </tr> <tr> <td rowspan="2" style="vertical-align: middle;">Ibandronate</td> <td class="divider_bottom" style="vertical-align: middle;">Oral<sup>¶</sup></td> <td class="divider_bottom"> <ul> <li>150 mg once monthly</li> </ul> </td> <td class="centered" rowspan="2" style="vertical-align: middle;">Yes</td> <td class="centered" rowspan="2" style="vertical-align: middle;">No</td> <td class="centered" rowspan="2" style="vertical-align: middle;">+/–</td> <td class="divider_bottom" style="vertical-align: middle;">Limited data</td> </tr> <tr> <td style="vertical-align: middle;">Intravenous</td> <td> <ul> <li>3 mg every 3 months</li> </ul> </td> <td style="vertical-align: middle;">Limited data</td> </tr> </tbody></table></div><div class="graphic_lgnd">Refer to UpToDate clinical topic reviews for detail on appropriate use of these agents. Dosing in this table is for adult patients with normal kidney function.</div><div class="graphic_footnotes">* For patients at low risk for fracture in the near future (eg, stable bone density, no previous vertebral or hip fractures), we suggest discontinuing therapy to reduce potential risks of long-term therapy, as there appears to be residual fracture benefit post-treatment.<br/>¶ Most oral bisphosphonates should be taken alone on an empty stomach first thing in the morning with at least 240 mL (8 oz) of water. After administration, the patient should not have food, drink, medications, or supplements and should remain upright for at least one half-hour (alendronate, risedronate) or one hour (ibandronate).<br/>Δ The 70 mg dose is also available in an effervescent formulation (dissolved over at least 5 minutes in 4 oz of tap water) and an oral solution (follow administration with at least 2 oz of water).<br/><font class="lozenge">◊</font> Based on indirect evidence from the alendronate extension trial.<br/>§ The enteric-coated, delayed-release formulation is taken immediately after breakfast with 4 oz of water.</div><div class="graphic_reference">References:

<ol>
<li>Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA 2006; 296:2927.</li>
<li>Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27:243.</li>
</ol></div><div id="graphicVersion">Graphic 131712 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
